Zhengye Biotechnology Holdings Inc.

Company Overview

Business Model: Zhengye Biotechnology Holding Limited, through its principal operating subsidiary Jilin Zhengye Biological Products Co., Ltd., is primarily engaged in the research, development, manufacturing, and sales of veterinary vaccines, with a core focus on vaccines for livestock. The company generates revenue through direct sales to livestock farmers and local governments, as well as through a distribution network that includes domestic and international partners.

Market Position: Jilin Zhengye operates in a highly competitive and rapidly evolving veterinary vaccine market in China. The company differentiates itself through a diversified product portfolio of 46 veterinary vaccines, high production quality adhering to Good Manufacturing Practices for Veterinary Drugs and ISO standards, and strong R&D capabilities supported by 52 employees and collaborations with leading Chinese universities and research institutes. Its products are distributed across 28 provincial regions in China and exported to Vietnam, Pakistan, and Egypt.

Recent Strategic Developments:

• Product Portfolio Expansion: Jilin Zhengye is expanding into household animal vaccines, having secured governmental approval for Rabies Vaccine, Inactivated (Strain Flury LEP) and completing clinical trials for Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine. It is also researching Feline Infectious Peritonitis Subunit Vaccine and Feline Leukemia and Feline Immunodeficiency Disease Duplex mRNA Vaccine, and conducting animal experiments for mRNA vaccines targeting Feline Infectious Peritonitis, Feline Immunodeficiency Virus, Porcine Epidemic Diarrhea, and Porcine Reproductive and Respiratory Syndrome.
• New Veterinary Drug Approvals: In February 2025, the Ministry of Agriculture and Rural Affairs approved Live Vaccine for Mycoplasma bovis (Strain HB150) as a Category I New Veterinary Drug. In March 2025, a Pentavalent Inactivated Vaccine for poultry diseases was also approved as a Category I New Veterinary Drug.
• Sales Strategy Realignment: The company has strategically realigned its sales practices to diversify its customer base and reduce concentration risk, resulting in a decrease in revenue from its largest customer.
• Initial Public Offering (IPO): Zhengye Biotechnology Holding Limited completed its IPO in January 2025, raising approximately US$6.9 million in gross proceeds, with Ordinary Shares commencing trading on the Nasdaq Capital Market under the ticker symbol "ZYBT."

Geographic Footprint: Jilin Zhengye's primary operations are located in China, with its office, storage, and manufacturing facilities in Jilin Economic & Technical Development Zone, Jilin Province. Its products are available in 28 provincial regions across China.

Cross-Border Operations: Jilin Zhengye exports its products to Vietnam, Pakistan, and Egypt. Key international sales include Newcastle Disease Virus (La Sota strain) and Avian influenza virus (H9 subtype HL strain) Vaccine, Inactivated (Pakistan, Vietnam), Newcastle Disease Vaccine, Live (La Sota strain) (Egypt, Vietnam), Newcastle Disease Vaccine, Live (Strain Clone 30) (Egypt), Newcastle Disease Vaccine, Inactivated (Egypt, Pakistan, Vietnam), Infectious Bursal Disease Vaccine, Live (Strain B87) (Vietnam), Bivalent Live Vaccine for Newcastle Disease and Infectious Bronchitis in Chickens (La Sota Strain+H120 Strain) (Vietnam, Pakistan), Newcastle Disease, Infectious Bronchitis and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain La Sota+Strain M41+Strain SY) (Vietnam), and Avian Pox Vaccine, Live (Quail-Adapted Strain) (Vietnam). The company's corporate structure includes subsidiaries in the British Virgin Islands (VVAX Skyline Holdings Limited, Windsor Holdings Co., Ltd.) and Hong Kong (Peg Biotechnology (HK) Holding Limited), which in turn hold equity interests in its PRC operating subsidiaries.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 49.0% (2024), 55.5% (2023), 56.8% (2022)
• Operating Margin: 8.8% (2024), 21.3% (2023), 25.3% (2022)
• Net Margin: 7.2% (2024), 17.7% (2023), 21.4% (2022)

Investment in Growth:

• R&D Expenditure: $1.8 million (6.9% of revenue)
• Capital Expenditures: $3.8 million
• Strategic Investments: Jilin Zhengye incurred RMB3.0 million (US$0.4 million) in accumulated costs for the "Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf)" project and RMB2.9 million (US$0.4 million) for the "Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology" project as of December 31, 2024.

Currency Impact Analysis:

• Foreign exchange impact on revenue and earnings: The company's reporting currency is RMB, while the functional currency of its BVI and Hong Kong subsidiaries is USD. Fluctuations in the RMB against the USD can affect the reported value of assets and results of operations when translated into USD.
• Hedging strategies and effectiveness: Jilin Zhengye entered into foreign currency swap contracts and cross-currency interest rate swap contracts in November 2024 with a commercial bank to manage exposure to JPY loans. These are non-designated derivative instruments, with changes in fair value recognized in other income.
• Functional currency considerations: The functional currencies of the PRC operating subsidiaries are their respective local currencies (RMB).

Business Segment Analysis

Swine Vaccines

Financial Performance:

• Revenue: $21.6 million (-16.5% YoY)
• Operating Margin: Not disclosed at segment level.
• Key Growth Drivers: The decrease in swine vaccine revenue from 2023 to 2024 was primarily due to veterinary vaccine market adjustments and a strategic realignment of sales practices aimed at diversifying the customer base and reducing concentration risk.

Product Portfolio: Jilin Zhengye offers a diverse range of swine vaccines, including Bivalent Inactivated Vaccine for Haemophilus parasuis, Subunit Vaccine of Porcine Circovirus Type 2, Swine Pseudorabies Vaccine, Inactivated, Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, Inactivated, and Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, among others.

Market Dynamics: The swine vaccine market is highly competitive. Jilin Zhengye's strategy includes diversifying its customer base to mitigate risks associated with high customer concentration, as its largest customer, Muyuan Foods Co., Ltd., accounted for 44.6% of total revenue in 2024.

Geographic Revenue Distribution:

• China: Swine vaccine sales are primarily domestic, with no international sales explicitly mentioned for this segment.

Poultry Vaccines

Financial Performance:

• Revenue: $2.1 million (+0.5% YoY)
• Operating Margin: Not disclosed at segment level.
• Key Growth Drivers: Revenue from poultry vaccines remained relatively stable, with minor fluctuations attributed to normal demand.

Product Portfolio: The segment includes vaccines such as Newcastle disease virus (La Sota strain) and Avian influenza virus (H9 subtype HL strain) Vaccine, Inactivated, Newcastle Disease Vaccine, Live (La Sota strain), Infectious Bursal Disease Vaccine, Live (Strain B87), and a newly approved Pentavalent Inactivated Vaccine for poultry diseases.

Market Dynamics: The poultry vaccine market is competitive. Jilin Zhengye aims to maintain its position through diversified products and R&D.

Geographic Revenue Distribution:

• Vietnam: Newcastle disease virus (La Sota strain) and Avian influenza virus (H9 subtype HL strain) Vaccine, Inactivated; Avian Pox Vaccine, Live (Quail-Adapted Strain); Newcastle Disease Vaccine, Live (LaSota strain); Newcastle Disease Vaccine, Inactivated; Combined Newcastle Disease and Infectious Bronchitis Vaccine, Live (Strain La Sota + Strain H52); Newcastle Disease, Infectious Bronchitis and Avian Influenza (H9 subtype) Vaccine, Inactivated (Strain La Sota + Strain M41 + Strain SY); Infectious Bursal Disease Vaccine, Live (Strain B87).
• Pakistan: Newcastle disease virus (La Sota strain) and Avian influenza virus (H9 subtype HL strain) Vaccine, Inactivated; Newcastle Disease Vaccine, Inactivated; Combined Newcastle Disease & Infectious Bronchitis Vaccine, Live (Strain La Sota + Strain H52).
• Egypt: Newcastle Disease Vaccine, Live (LaSota strain); Newcastle Disease Vaccine, Live (Strain Clone 30); Newcastle Disease Vaccine, Inactivated.

Other Vaccines (Bovine, Ovine, Canine)

Financial Performance:

• Revenue: $1.8 million (+78.9% YoY)
• Operating Margin: Not disclosed at segment level.
• Key Growth Drivers: The significant increase in revenue from other vaccines was driven by increased sales of vaccines for sheep.

Product Portfolio: This segment includes vaccines for bovine and ovine species such as Ovine Braxy, Struck, Lamb Dysentery, Enterotoxaemia, Vaccine, Inactivated, Caprine Infectious Pleuropneumonia Vaccine, Inactivated, and Goat Pox Vaccine, Live. It also includes the Rabies Vaccine, Inactivated (Strain Flury LEP) for canine use, which is production-ready, and feline vaccines in development.

Market Dynamics: Jilin Zhengye is actively preparing to enter the household animal vaccines market, indicating a strategic expansion beyond traditional livestock.

Geographic Revenue Distribution:

• China: Sales are primarily domestic for these categories.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries: Zhengye Biotechnology Holding Limited (Cayman Islands) is the ultimate holding company. It owns VVAX Skyline Holdings Limited (BVI), which owns Peg Biotechnology (HK) Holding Limited (Hong Kong), which in turn owns Hainan Senhan Biotechnology Co., Ltd. (PRC). Jilin Zhengye Biological Products Co., Ltd. (PRC) is 58.689% owned by Hainan Senhan and 25.1524% by Windsor Holdings Co., Ltd. (BVI), which is 100% owned by VVAX Skyline. Beijing Zhongnong Zhengye Biotechnology Co., Ltd. (PRC) is 51.00% owned by Jilin Zhengye.
• Joint Ventures: Not explicitly mentioned as joint ventures, but Jilin Zhengye engages in cooperative R&D with various Chinese universities and research institutes.
• Licensing Agreements: Jilin Zhengye has technology licensing agreements with Harbin Veterinary Research Institute for Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, Live, and with China Agricultural University and China Institute of Veterinary Drug Control for Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated.

Cross-Border Trade:

• Export Markets: Primary export destinations include Vietnam, Pakistan, and Egypt for various poultry vaccines.
• Import Dependencies: Not explicitly detailed, but raw materials for manufacturing are purchased from certified and qualified suppliers in China.
• Transfer Pricing: Not explicitly detailed in the provided text.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: $28 (RMB0.2 million) declared in 2024, $7.5 million (RMB55.1 million) in 2023, and $2.4 million (RMB17.7 million) in 2022. Cash paid for dividends was $2.2 million (RMB16.0 million) in 2024.
• Dividend Yield: Not disclosed.
• Future Capital Return Commitments: The company intends to retain future earnings to finance business expansion and does not anticipate paying cash dividends in the foreseeable future.

Balance Sheet Position:

• Cash and Equivalents: $2.5 million (RMB18.6 million) as of December 31, 2024.
• Total Debt: $11.8 million (RMB86.4 million) as of December 31, 2024.
• Net Cash Position: -$9.3 million (RMB-67.8 million) as of December 31, 2024.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: As of December 31, 2024, $10.2 million (RMB74.4 million) in short-term loans and $0.985 million (RMB7.19 million) in current maturities of long-term loans are due within one year. An additional $0.658 million (RMB4.8 million) in long-term loans is due between 1-3 years.

Cash Flow Generation:

• Operating Cash Flow: $5.6 million (RMB41.0 million) in 2024.
• Free Cash Flow: Not explicitly stated.
• Cash Conversion Metrics: Not explicitly stated.

Currency Management:

• Cash holdings by major currencies: Primarily in RMB.
• Natural hedging through operational diversification: Not explicitly detailed.
• Financial hedging instruments and strategies: Jilin Zhengye uses foreign currency swap contracts and cross-currency interest rate swap contracts to manage foreign exchange and interest rate risks, particularly for JPY-denominated loans.

Operational Excellence

Production & Service Model: Jilin Zhengye focuses on the research, development, manufacturing, and sales of veterinary vaccines. Its production lines are located in Jilin Economic & Technical Development Zone, Jilin Province, China, operating 8 hours per day, 280-320 days per year. The production process is subject to continuous review and monitoring by a quality control team, covering raw materials, viral seeds inspection, work-in-process checks, and final product examination.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Raw Materials: All raw and auxiliary materials (serum, culture medium, adjuvant, hatching egg, experimental animals) are purchased from certified and qualified suppliers in China.
• Supplier Concentration: In 2024, Suzhou Womei Biology Co., Ltd. accounted for 14.2% of total purchases. In 2022, Xinxiang Jiexin Biotechnology Co., Ltd. and Henan Shuocheng Biotechnology Co., Ltd. accounted for 25.3% and 12.9% of total purchases, respectively.
• Technology Partners:
  • Harbin Veterinary Research Institute: Partnered for R&D and technology licensing, including Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, Live.
  • Shanghai Veterinary Research Institute: Strategic cooperation for R&D of veterinary vaccines, including Duck Tembusu Viral Disease Vaccine, Live.
  • China Agricultural University: Partnered for R&D and technology licensing, including Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated.
  • Jilin University, Nanjing Agricultural University, Jilin Academy of Agricultural Sciences, Jilin Agricultural University, Jilin Institute of Animal Husbandry and Veterinary Medicine, Jilin Provincial Center for Animal Disease Prevention and Control, Huazhong Agricultural University, Pulike: Collaborators on various R&D projects.

Facility Network:

• Manufacturing: Three veterinary vaccine production floors with 13 vaccine production lines in Jilin Economic & Technical Development Zone, Jilin Province, China, covering an aggregate building area of approximately 396,975 square feet.
• Research & Development: One R&D center established in 2006 in Jilin Economic & Technical Development Zone, Jilin Province, China, with 52 employees.
• Distribution: Warehousing and distribution facilities are primarily located in Jilin Economic & Technical Development Zone, Jilin Province, China, with additional leased properties in Jilin and Jinan for warehouses and residences.

Operational Metrics:

• Annual Production Capacity (2024):
  • Swine Vaccine: 233,045,107 doses
  • Poultry Vaccine: 1,338,417,200 doses
  • Bovine and Ovine Vaccine: 76,490,380 doses
• Quality Control: Comprehensive quality management system compliant with Good Manufacturing Practices for Veterinary Drugs, ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018, covering raw materials, work-in-process, and finished product inspection (physical property, sterility, safety, efficacy testing).

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Accounts for 65.3% of revenue in 2024. This includes participating in tenders and procurement by major breeding companies and direct contracts with livestock farmers.
• Channel Partners: Accounts for 32.1% of revenue in 2024. This network covers 28 provincial-level administrative regions in China and includes exporting distributors in Vietnam, Pakistan, and Egypt, primarily sourced through Alibaba.com.
• Government Platforms: Accounts for 2.6% of revenue in 2024. This involves participating in government tender and procurement processes by provincial-level veterinary authorities for annual vaccine procurement.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Muyuan Foods Co., Ltd. ("MYF") is a major customer, accounting for 44.6% of total revenue in 2024 (down from 52.1% in 2023 and 74.5% in 2022). Shuangbaotai (Group) Corporation Limited was another significant customer in 2023, accounting for 15.0% of total revenue.
• Strategic Partnerships: Long-term written sales agreements (1-3 years) are maintained with direct-end user livestock farmers. International sales are typically governed by short-form order sheets.
• Customer Concentration: High customer concentration risk exists with MYF, which accounted for 49.0% of total accounts receivable as of December 31, 2024. The company is actively diversifying its customer base to mitigate this risk.

Regional Market Penetration:

• China: Products are available in 28 provincial regions.
• Growth Markets: Export markets include Vietnam, Pakistan, and Egypt, with international sales revenue growing significantly (82.4% YoY in 2024). The company intends to expand its sales and distribution network to new geographic markets, including countries in Southeast Asia (e.g., Thailand, Philippines) and cities with developed animal husbandry in China (e.g., Gongzhuling City, Gaomi City, Xuanwei City).

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The veterinary vaccine industry in China is highly competitive and rapidly evolving, characterized by many new entrants and a few leading companies. Competition is intense, with technological advancements from biopharmaceutical and biotechnology companies. The market is influenced by animal disease prevalence, temperature changes affecting animal immunity, and increasing awareness of epidemic prevention among livestock farmers.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Jinyu Bio-Technology Co., Ltd.: Global competitive overlap in vaccines for Swine, Poultry, Cattle, Sheep, and Goat.
• Wuhan Keqian Biology Co., Ltd.: Competitive overlap in vaccines for Swine and Poultry.
• Shanghai Shenlian Biomedical Co., Ltd.: Competitive overlap in vaccines for Swine.
• Guangdong Yongshun Biopharmaceutical Co., Ltd.: Competitive overlap in vaccines for Swine and Poultry.
• Shanghai Haili Biotechnology Co., Ltd.: Competitive overlap in vaccines for Swine and Poultry.

Regional Competitive Dynamics: Jilin Zhengye competes based on price, value, customer support, brand recognition, reputation, and product functionality, reliability, and compatibility. Larger, well-capitalized competitors may have greater resources for product development, marketing, and sales.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics:

• Veterinary Vaccine Market Adjustments: The company's revenue decreased in 2023 and 2024 due to market adjustments and a strategic realignment of sales practices.
• Technology Disruption: The market for Jilin Zhengye's products could be negatively impacted by new or alternative products (e.g., "green" or "holistic" health products, disease-resistant animals) or technological breakthroughs by competitors.
• Customer Concentration: High dependence on major customers (e.g., Muyuan Foods Co., Ltd. accounted for 44.6% of total revenue in 2024) exposes the company to risks of significant fluctuations or declines in revenue if these customers reduce purchases or switch to competitors. Geographic diversification is a mitigation strategy.

Operational & Execution Risks

Global Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on a limited number of suppliers for raw materials (e.g., one vendor accounted for 14.2% of total purchases in 2024) poses a risk of disruption if suppliers are lost or unable to deliver.
• Regional Disruptions: Production interruptions can be caused by factors such as natural disasters, power outages, labor problems, or outbreaks of highly contagious diseases near production sites.
• Trade Restrictions: Unfavorable government policies on international trade, such as capital controls or tariffs, could affect demand for products, competitive position, or ability to conduct business in certain countries.

Financial & Regulatory Risks

Currency & Financial Risks:

• Foreign Exchange: Fluctuations in the RMB against the U.S. dollar and other currencies can materially and adversely affect cash flows, revenue, and financial condition, especially for international sales and conversion of IPO proceeds. Limited hedging options are available in China.
• Interest Rate Risk: Exposure to interest rate risk on interest-bearing assets and liabilities, though the company has not been exposed to material risks from changes in market interest rates to date.
• Credit & Liquidity: The company relies on cash generated from operating and financing activities. PRC regulations restrict the ability of PRC subsidiaries to pay dividends or make other payments to the holding company, potentially affecting liquidity.

Regulatory & Compliance Risks:

• Multi-Jurisdictional Compliance: Operations in China are subject to extensive and rapidly evolving PRC laws and regulations, including those related to foreign investment, veterinary drug production and operation, environmental protection, product quality, and intellectual property. Uncertainties in interpretation and enforcement, and quick changes in policies, could limit legal protection.
• Trade Regulations: Export and import activities are subject to PRC regulations, requiring record filing and registration.
• Tax Regulations: Potential classification as a PRC "resident enterprise" could result in unfavorable tax consequences (25% EIT on worldwide income, withholding tax on dividends). Indirect transfers of equity interests in PRC resident enterprises by non-PRC holding companies face uncertainty regarding tax assessment. Dividends from PRC subsidiaries to offshore subsidiaries may not qualify for certain treaty benefits (e.g., 5% withholding tax rate under Double Tax Avoidance Arrangement with Hong Kong).
• Overseas Listing Regulations: Subject to CSRC filing procedures for overseas securities offerings and listings, and potential cybersecurity and data security reviews by the CAC. The HFCA Act and AHFCAA pose risks of delisting if PCAOB inspections of auditors are obstructed for two consecutive years.

Geopolitical & External Risks

Country-Specific Risks:

• Political Risk: Changes in China's economic, political, or social conditions or government policies could materially affect business and operations. Government intervention or influence over operations is a significant risk.
• Economic Risk: Adverse changes in economic conditions in China, or government control over capital investments, could negatively affect business.
• Regulatory Changes: New or stricter regulations, or changes in interpretation, could increase compliance costs or restrict operations.
• International Trade Tension: Current tensions, particularly between the United States and China, may adversely impact business, financial condition, and results of operations, especially if the company expands internationally.

Innovation & Technology Leadership

Research & Development Focus: Jilin Zhengye focuses on developing new products and improving existing ones to meet market needs. Key R&D areas include:

• Livestock Vaccines: Continued development of vaccines for swine, poultry, bovine, and ovine species.
• Household Animal Vaccines: Active development of feline and canine vaccines, including Rabies Vaccine, Inactivated (Strain Flury LEP), Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine, Feline Infectious Peritonitis Subunit Vaccine, and Feline Leukemia and Feline Immunodeficiency Disease Duplex mRNA Vaccine.
• mRNA Vaccines: Exploring mRNA vaccine technology for Feline Infectious Peritonitis, Feline Immunodeficiency Virus, Porcine Epidemic Diarrhea, and Porcine Reproductive and Respiratory Syndrome.

Global R&D Network:

• R&D Center Location: One R&D center established in 2006 at No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, China.
• Innovation Pipeline: As of December 31, 2024, the R&D center has developed 45 patents and contributed to 16 Registration Certificates of New Veterinary Drugs. The company has several R&D projects, some of which are subsidized by the Government of Jilin Province.
• Technology Development: The company expects R&D expenses to increase significantly as it develops new products and technologies.

Intellectual Property Portfolio:

• Patent Strategy: Jilin Zhengye holds 45 registered patents in mainland China, including invention patents (e.g., preparation methods for live pseudorabies vaccine, H9N2 avian influenza virus strain) and utility models (e.g., aseptic sampling devices, vaccine storage devices).
• Licensing Programs: The company licenses vaccine production technologies and related intellectual properties from partners like Harbin Veterinary Research Institute and China Agricultural University.
• IP Litigation: Not explicitly mentioned in the provided text.

Technology Partnerships:

• Strategic Alliances: Long-term cooperative relationships with China Agricultural University, Nanjing Agricultural University, Jilin University, Harbin Veterinary Research Institute, Huazhong Agricultural University, Shanghai Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Jilin Academy of Agricultural Sciences, Jilin Agricultural University, Jilin Institute of Animal Husbandry and Veterinary Medicine, Jilin Provincial Center for Animal Disease Prevention and Control, and Pulike. These collaborations focus on early-stage basic research, pilot studies, and industrialization research.

Leadership & Governance

Executive Leadership Team

International Management Structure: The company has a centralized management structure with executive officers overseeing operations, and regional leadership for sales and distribution within China and for international markets.

Board Composition: The board of directors consists of five directors, including three independent directors (Jiayao Wu, Wenbing Wang, Ping Jiang). Jiayao Wu is the chairperson of the audit committee and qualifies as an audit committee financial expert. The company has established an audit committee, a compensation committee, and a nominating and corporate governance committee. As a foreign private issuer, the company takes advantage of exemptions from certain Nasdaq corporate governance standards, such as not requiring a majority of independent directors on the board or fully independent compensation and nominating/corporate governance committees.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: Primary Regulatory Environments:

• China (PRC): Subject to the Company Law, Foreign Investment Law (including the Negative List), Regulation on Veterinary Drug Administration, Measures for the Administration of the Production and Quality Control of Veterinary Biological Products, Norms for the Business Operation and Quality Management of Veterinary Drugs, Measures for the Administration of the Business Operation of Veterinary Biological Products, Measures for the Administration of Veterinary Drug Registration, Regulation on the Administration of Laboratory Animals, Product Quality Law, Environmental Protection Law, Law on the Prevention and Control of Environmental Pollution Caused by Solid Waste, Regulations on Urban Drainage and Sewage Treatment, Consumer Rights and Interests Protection Law, Foreign Exchange Administration Regulations, EIT Law, VAT Law, PRC Labor Law, PRC Labor Contract Law, Social Insurance Law, Regulations on the Administration of Housing Funds, M&A Rules, and Overseas Listing Trial Measures.
• Hong Kong: Subject to Hong Kong profits tax regime.
• Cayman Islands: Governed by the Cayman Companies Act, with no income or capital gains tax.

Cross-Border Compliance:

• Export Controls: Export and import of goods and technology require record filing and registration with MOFCOM and Customs.
• Sanctions Compliance: Not explicitly detailed, but general compliance with international trade regulations is implied.
• Anti-Corruption: Subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws, with policies mandating compliance.

International Tax Strategy:

• Transfer Pricing: Not explicitly detailed in the provided text.
• Tax Treaties: Dividends from PRC subsidiaries to Hong Kong subsidiaries may be subject to a 10% withholding tax, potentially reduced to 5% under the Double Tax Avoidance Arrangement if certain conditions are met (e.g., 25% ownership for 12 consecutive months, beneficial owner status). Jilin Zhengye has not yet applied for the tax resident certificate from Hong Kong tax authority.
• BEPS Compliance: Not explicitly detailed in the provided text.

Environmental & Social Impact

Global Sustainability Strategy: Environmental Commitments: Jilin Zhengye's production activities are governed by PRC environmental laws and regulations. The company has invested RMB530,438 in pollutant treatment from July 2022 to December 2024.

• Climate Strategy: Not explicitly detailed.
• Carbon Neutrality: Not explicitly detailed.
• Renewable Energy: Not explicitly detailed.

Regional Sustainability Initiatives:

• China: Wastewater is treated (high-temperature sterilization and inspection for active toxic sewage) before disposal into municipal pipelines. Solid wastes are collected and sent for recycling or municipal disposal.
• Supply Chain: Not explicitly detailed.

Social Impact by Region:

• Community Investment: Not explicitly detailed.
• Labor Standards: Jilin Zhengye complies with PRC labor laws, including written labor contracts, minimum wage standards, and statutory employee benefits (pension, medical, unemployment, maternity, work-related injury insurance, and housing fund plans). The company maintains good working relationships with employees and has not experienced material labor disputes.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies:

• Transaction Hedging: Jilin Zhengye entered into foreign currency swap contracts and cross-currency interest rate swap contracts in November 2024 to manage JPY loan exposure, with termination dates in November 2025.
• Translation Hedging: Not explicitly detailed.
• Economic Hedging: Not explicitly detailed.